Xtant Medical Holdings, Inc. (XTNT) Dividend History

Xtant Medical Holdings, Inc. is a medical device company specializing in regenerative solutions and biologics for use in spine, trauma, and infection management. The company focuses on developing and commercializing products derived from human tissues and other biomaterials to support tissue repair and regeneration in various surgical procedures.

Dividend History

Xtant Medical Holdings, Inc. currently does not pay dividends

Company News

  • Xtant Medical Announces Launch of SimpliGraft™ and SimpliMax™ for Chronic and Acute Wounds

    BELGRADE, Mont., April 30, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the full commercial launch of two amniotic membrane allografts, SimpliGraft™ and SimpliMax™.

    GlobeNewswire Inc.
  • Xtant Medical Announces Record Full Year 2023 Revenue of $91.3 Million

    Establishes Full Year 2024 Revenue Guidance of $112 Million - $116 Million

    GlobeNewswire Inc.
  • Xtant Medical to Issue Fourth Quarter and Full Year 2023 Financial Results on April 1, 2024

    BELGRADE, Mont., March 21, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2023, before the open of the financial markets on Monday, April 1, 2024.

    GlobeNewswire Inc.
  • Xtant Medical Increases Revolving Credit Facility to $17 Million with MidCap Financial

    BELGRADE, Mont., March 07, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that the Company’s revolving credit agreement with MidCap Financial Trust (“MidCap”) was amended to increase the commitment from $8.0 million to $17.0 million. The Company’s term loan was also amended to provide for an additional $10.0 million tranche, to be made available for acquisitions at MidCap’s discretion. The maturity dates of Xtant’s revolving credit facility and term loan were extended to March 1, 2029 and minimum net product revenue requirements specified in the agreements were reset and minimum Adjusted EBITDA requirements were removed. Additionally, the applicable margin used to determine the per annum interest rate of the term loan was reduced from 7.00% to 6.50%.

    GlobeNewswire Inc.
  • Xtant Medical to Participate in Upcoming Investor Conferences

    BELGRADE, Mont., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that management will participate in two upcoming investor conferences:

    GlobeNewswire Inc.
Dividend data last updated 06/07/2025 20:04:57 UTC